Research Article
Extended Renal Outcomes with Use of Iodixanol versus Iohexol after Coronary Angiography
Table 2
Extended renal outcomes in patients (cohort A) with CI-AKI versus none.
| | Total 560 patients (cohort A) | Non-CI-AKI | CI-AKI | value | | |
| | Age > 65 years, No. (%) | 218 (47.3) | 64 (64.7) | 0.002 | | Male gender, No. (%) | 334 (72.5) | 55 (55.6) | 0.001 | | Comorbidities, No. (%) | | | | | Diabetes mellitus | 70 (15.2) | 23 (23.2) | 0.05 | | Hypertensive heart disease | 281 (61.0) | 56 (56.6) | 0.42 | | CCF | 34 (7.4) | 25 (25.3) | <0.001 | | Critical illness (within 1 week after contrast) | 28 (6.1) | 25 (25.3) | <0.001 | | Baseline renal function | | | | | eGFR* < 60 mL/min/1.73 m2, No. (%) | 120 (26.0) | 18 (18.2) | 0.10 | | eGFR* < 30 mL/min/1.73 m2, No. (%) | 45 (9.8) | 12 (12.1) | 0.48 | | Iohexol (vs iodixanol), No. (%) | 229 (49.7) | 34 (34.3) | 0.006 | | Iodine dose per unit eGFR, median (IQR) | 0.68 (0.45–1.04) | 0.60 (0.40–0.89) | 0.06 | | Iodine dose per unit eGFR > 0.7, No. (%) | 214 (46.4) | 37 (37.4) | 0.10 | | ΔCr at 3-days, median (IQR), μmol/L | 0 (−5–9) | 31 (24–55) | <0.0001 | | Extended renal outcomes | | | | | At 6-months () | | | | | ΔCr, median (IQR), μmol/L | 10 (−1–27) | 39 (25–45) | 0.0005 | | RIFLE “R/I/F”#, No. (%) | 17 (25.8) | 13 (81.3) | <0.001 | | RIFLE “I/F”#, No. (%) | 3 (4.5) | 2 (12.5) | 0.25 | | At 1-year () | | | | | ΔCr, median (IQR), μmol/L | 9 (−5–32) | 17 (6–43) | 0.23 | | RIFLE “R/I/F”#, No. (%) | 21 (29.2) | 4 (50.0) | 0.25 | | RIFLE “I/F”#, No. (%) | 7 (9.7) | 2 (25.0) | 0.22 |
|
|
*4-variable MDRD eGFR equation; #RIFLE acute kidney injury classification (“R/I/F” refers to “at-risk/injury/failure” classes, respectively).
Δ: delta (change in); eGFR: estimated glomerular filtration rate; IQR: interquartile range; No.: number; pts: patients; sCr: serum creatinine; SD: standard deviation; vs: versus.
|
